https://glenmarkpharma.com/other_announcements/disclosure-under-regulation-30-of-sebi-listing-obligations-and-disclosures-requirements-regulations-2015/ 2026-01-13T11:43:50+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-to-launch-mixed-amphetamines-immediate-release-tablets/ 2026-01-14T11:27:08+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-launches-vancomycin-hydrochloride-for-injection-usp-750-mg-vial-1-25-g-vial-and-1-5-g-vial-single-dose-vial/ 2026-01-14T11:27:23+00:00 https://glenmarkpharma.com/other_announcements/gccl-transaction-completion-letter/ 2026-01-14T11:27:36+00:00 https://glenmarkpharma.com/other_announcements/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosures-requirements-regulations-2015/ 2026-01-14T11:27:59+00:00 https://glenmarkpharma.com/other_announcements/credit-rating-rationale-crisil/ 2026-01-14T11:28:25+00:00 https://glenmarkpharma.com/other_announcements/board-meeting-intimation/ 2026-01-14T11:29:05+00:00 https://glenmarkpharma.com/other_announcements/appointment-of-senior-management-personnel-of-the-company/ 2026-01-14T11:29:33+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-postal-ballot-notice/ 2026-01-14T11:30:47+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-postal-ballot-notice-2/ 2026-01-14T11:31:10+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement/ 2026-01-14T11:32:02+00:00 https://glenmarkpharma.com/other_announcements/intimation-under-regulation-305-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015/ 2026-01-14T11:32:19+00:00 https://glenmarkpharma.com/other_announcements/intimation-regarding-upfront-payment-received/ 2026-01-14T11:32:41+00:00 https://glenmarkpharma.com/other_announcements/incorporation-of-glenmark-consumer-care-limited/ 2026-01-14T11:33:00+00:00 https://glenmarkpharma.com/other_announcements/grant-of-esops/ 2026-01-14T11:33:16+00:00 https://glenmarkpharma.com/other_announcements/q1-fy-2026-results-newspaper-advertisement/ 2026-01-14T11:35:18+00:00 https://glenmarkpharma.com/other_announcements/outcome-of-board-meeting-held-on-26th-september-2025/ 2026-01-14T11:35:54+00:00 https://glenmarkpharma.com/other_announcements/notice-of-postal-ballot-disclosure-under-regulation-30-of-the-sebi-lodr-regulations-2015/ 2026-01-14T11:36:04+00:00 https://glenmarkpharma.com/other_announcements/notice-of-postal-ballot-disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015/ 2026-01-14T11:36:17+00:00 https://glenmarkpharma.com/other_announcements/update-acquisition-of-securities-of-o2-renewable-energy-xxiv-private-limited/ 2026-01-14T11:36:54+00:00 https://glenmarkpharma.com/other_announcements/transfer-of-the-companys-consumer-care-business/ 2026-01-14T11:37:36+00:00 https://glenmarkpharma.com/other_announcements/result-of-postal-ballot-by-remote-e-voting-scrutinizers-report-2/ 2026-01-14T11:37:51+00:00 https://glenmarkpharma.com/other_announcements/result-of-postal-ballot-by-remote-e-voting-scrutinizers-report/ 2026-01-14T11:38:05+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-launches-pioneering-nutrition-program-to-fight-malnutrition-in-the-philippines/ 2026-01-14T11:41:13+00:00 https://glenmarkpharma.com/other_announcements/glenmark-receives-anda-approval-for-olopatadine-hydrochloride-ophthalmic-solution-usp-0-2-otc/ 2026-01-14T11:42:53+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharma-expands-cardiometabolic-portfolio-with-the-launch-of-empagliflozin-and-its-fixed-drug-combinations-in-india/ 2026-01-14T11:44:58+00:00 https://glenmarkpharma.com/other_announcements/glenmark-therapeutics-inc-usa-launches-polyethylene-glycol-3350-powder-for-solution-17-grams-capful-otc/ 2026-01-14T11:47:30+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-launches-acquires-and-launches-acetylcysteine-injection-6-gm-30-ml-200-mg-ml-single-dose-vials/ 2026-01-14T11:50:18+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-launches-epinephrine-injection-usp-10-mg-10-ml-1-mg-ml-multiple-dose-vial/ 2026-01-14T11:52:54+00:00 https://glenmarkpharma.com/other_announcements/q3-fy-2025-results-newspaper-advertisement/ 2026-01-14T11:55:22+00:00 https://glenmarkpharma.com/other_announcements/u-s-fda-inspection-at-the-companys-facility-at-indore-madhya-pradesh-india/ 2026-01-14T12:06:33+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-launches-latanoprost-ophthalmic-solution-0-005/ 2026-01-14T12:20:26+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-launches-clindamycin-phosphate-foam-1/ 2026-01-14T12:24:40+00:00 https://glenmarkpharma.com/other_announcements/intimation-under-regulation-30-of-sebi-lodr/ 2026-01-14T12:27:14+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-inc-usa-launches-phytonadione-injectable-emulsion-usp-10-mg-ml-single-dose-ampules/ 2026-01-14T12:36:44+00:00 https://glenmarkpharma.com/other_announcements/intimation-of-change-in-the-name-of-the-step-down-wholly-owned-subsidiaries-of-the-company/ 2026-01-14T12:39:17+00:00 https://glenmarkpharma.com/other_announcements/glenmark-is-the-first-to-launch-biosimilar-of-popular-anti-diabetic-drug-liraglutide-in-india/ 2026-02-02T08:50:51+00:00 https://glenmarkpharma.com/other_announcements/jiangsu-alphamab-biopharmaceuticals-3d-medicines-beijing-and-glenmark-announce-the-signing-of-a-license-agreement-for-kn035-envafolimab-for-multiple-geographies-around-the-world/ 2026-02-02T08:53:36+00:00 https://glenmarkpharma.com/other_announcements/glenmark-and-ichnos-take-a-collaborative-leap-to-accelerate-innovation-in-cancer-treatment-with-their-alliance-%e2%80%90-ichnos-glenmark-innovation/ 2026-02-02T08:57:39+00:00 https://glenmarkpharma.com/other_announcements/board-meeting-intimation-14-february-2024/ 2026-02-02T08:59:51+00:00 https://glenmarkpharma.com/other_announcements/glenmark-partners-with-pfizer-to-launch-abrocitinib-in-india/ 2026-02-02T09:01:48+00:00 https://glenmarkpharma.com/other_announcements/q3-fy-24-earnings-call-invitation-february-16-2024/ 2026-02-02T09:04:42+00:00 https://glenmarkpharma.com/other_announcements/allotment-of-equity-shares-under-glenmark-pharmaceuticals-limited-esop-scheme-2016/ 2026-02-02T09:06:53+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-ltd-reports-consolidated-revenue-of-rs-29096-mn-for-q3-fy-2023-24/ 2026-02-02T09:09:15+00:00 https://glenmarkpharma.com/other_announcements/glenmarks-mda-q3-fy-2023-24/ 2026-02-02T09:11:32+00:00 https://glenmarkpharma.com/other_announcements/glenmarks-q3-fy-2023-24-results/ 2026-02-02T09:16:01+00:00 https://glenmarkpharma.com/other_announcements/glenmarks-q3-fy-2023-24-results-newspaper-advertisement/ 2026-02-02T09:18:23+00:00 https://glenmarkpharma.com/other_announcements/intimation-of-schedule-of-analyst-institutional-investor-meeting-february-2024/ 2026-02-02T09:20:11+00:00 https://glenmarkpharma.com/other_announcements/disclosure-pursuant-to-regulation-307-of-sebi-lodr/ 2026-02-02T09:23:20+00:00 https://glenmarkpharma.com/other_announcements/disclosure-pursuant-to-regulation-307-of-sebi-lodr-2/ 2026-02-02T09:26:24+00:00 https://glenmarkpharma.com/other_announcements/credit-ratings-rating-research-update-issued-by-sp-global-ratings/ 2026-02-02T09:28:31+00:00 https://glenmarkpharma.com/other_announcements/credit-ratings-rating-research-update-issued-by-crisil-ratings/ 2026-02-02T09:31:22+00:00 https://glenmarkpharma.com/other_announcements/retirement-of-independent-directors/ 2026-02-02T09:33:34+00:00 https://glenmarkpharma.com/other_announcements/compliance-certificate-under-regulation-73-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-for-the-financial-year-ended-31st-march-2024/ 2026-02-02T09:49:18+00:00 https://glenmarkpharma.com/other_announcements/certificate-from-practicing-company-secretary-under-regulation-409-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-for-the-financial-year-ended-31st-march-2024/ 2026-02-02T09:57:20+00:00 https://glenmarkpharma.com/other_announcements/credit-ratings-rating-rationale-issued-by-india-ratings-and-research/ 2026-02-02T10:02:11+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-acetaminophen-and-ibuprofen-tablets-250-mg-125-mg-otc/ 2026-02-02T10:05:47+00:00 https://glenmarkpharma.com/other_announcements/intimation-of-acquisition/ 2026-02-02T10:11:13+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-brimonidine-tartrate-and-timolol-maleate-ophthalmic-solution-0-20-5/ 2026-02-02T10:19:53+00:00 https://glenmarkpharma.com/other_announcements/investor-day-intimation/ 2026-02-02T10:23:36+00:00 https://glenmarkpharma.com/other_announcements/glenmark-and-beigene-enter-into-an-agreement-for-marketing-and-distribution-of-tislelizumab-and-zanubrutinib-in-india/ 2026-02-02T10:27:15+00:00 https://glenmarkpharma.com/other_announcements/glenmarks-q4-fy-2023-24-results-newspaper-advertisement/ 2026-02-02T10:40:46+00:00 https://glenmarkpharma.com/other_announcements/glenmark-receives-anda-approval-for-esomeprazole-magnesium-delayed-release-capsules-usp-20-mg-otc/ 2026-02-02T10:42:35+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-topiramate-capsules-usp-15-mg-and-25-mg/ 2026-02-02T10:45:28+00:00 https://glenmarkpharma.com/other_announcements/glenmarks-q1-fy-2024-25-results-newspaper-advertisement/ 2026-02-02T11:45:26+00:00 https://glenmarkpharma.com/other_announcements/agm-date-intimation/ 2026-02-02T11:53:35+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-2/ 2026-02-02T11:59:29+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-3/ 2026-02-02T12:25:21+00:00 https://glenmarkpharma.com/other_announcements/outcome-and-result-of-agm/ 2026-02-02T12:27:23+00:00 https://glenmarkpharma.com/other_announcements/q2-fy-2025-results-newspaper-advertisement/ 2026-02-02T13:27:42+00:00 https://glenmarkpharma.com/other_announcements/first-results-of-a-phase-1-first-in-human-dose-escalation-study-of-isb-2001-a-bcmaxcd38xcd3-targeting-trispecific-antibody-in-patients-with-relapsed-refractory-multiple-myeloma-rrmm/ 2026-02-02T13:30:22+00:00 https://glenmarkpharma.com/other_announcements/update-on-acquisition-of-securities-of-o2-renewable-energy-xxiv-private-limited/ 2026-02-02T13:33:34+00:00 https://glenmarkpharma.com/other_announcements/intimation-of-schedule-of-analyst-institutional-investor-meetings-november-2023/ 2026-02-06T11:00:24+00:00 https://glenmarkpharma.com/other_announcements/result-of-postal-ballot-by-remote-e-voting-scrutinizers-report-3/ 2026-02-06T11:02:56+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-fluphenazine-hydrochloride-tablets-usp-1-mg-2-5-mg-5-mg-and-10-mg/ 2026-02-06T11:05:20+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharma-is-first-to-launch-a-triple-drug-fdc-of-teneligliptin-dapagliflozin-metformin-in-india-for-type-2-diabetes-in-adults-with-co-morbidities/ 2026-02-06T11:08:31+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-apremilast-tablets-10-mg-20-mg-and-30-mg/ 2026-02-06T11:11:21+00:00 https://glenmarkpharma.com/other_announcements/ichnos-sciences-enters-licensing-agreement-for-ox40-antagonist-monoclonal-antibody-portfolio-with-astria-therapeutics-oct-23/ 2026-02-06T11:13:17+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-postal-ballot-notice-3/ 2026-02-06T11:16:16+00:00 https://glenmarkpharma.com/other_announcements/notice-of-postal-ballot-disclosure-under-regulation-30-of-the-sebi-lodr-regulations-2015-2/ 2026-02-06T11:18:20+00:00 https://glenmarkpharma.com/other_announcements/credit-ratings-rating-rationale-issued-by-india-ratings-and-research-2/ 2026-02-06T11:20:22+00:00 https://glenmarkpharma.com/other_announcements/credit-rating-crisil-rating-rationale/ 2026-02-06T11:23:12+00:00 https://glenmarkpharma.com/other_announcements/credit-rating-glenmark-pharmaceuticals-outlook-revised-to-positive-on-proposed-gls-stake-sale-bb-rating-affirmed/ 2026-02-06T11:24:34+00:00 https://glenmarkpharma.com/other_announcements/cosmo-and-glenmark-announce-the-signing-of-distribution-and-license-agreements-for-winlevi-in-europe-and-south-africa/ 2026-02-06T11:28:06+00:00 https://glenmarkpharma.com/other_announcements/credit-rating-india-ratings-has-discontinued-and-withdrawn-the-outstanding-voluntary-issuer-ratings-disclosure-due-to-regulatory-requirements/ 2026-02-06T11:30:19+00:00 https://glenmarkpharma.com/other_announcements/intimation-of-analyst-investor-meet-september-2023/ 2026-02-06T11:33:09+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharma-announces-proposed-divestment-of-majority-stake-in-glenmark-life-sciences/ 2026-02-06T11:35:51+00:00 https://glenmarkpharma.com/other_announcements/change-in-senior-management-september-2023/ 2026-02-06T11:38:46+00:00 https://glenmarkpharma.com/other_announcements/intimation-of-45th-annual-general-meeting/ 2026-02-06T11:46:53+00:00 https://glenmarkpharma.com/other_announcements/press-release-of-our-wholly-owned-subsidiary-company-relating-to-antitrust-settlement-with-doj/ 2026-02-06T11:48:57+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-sanda-approval-for-tacrolimus-ointment-0-03/ 2026-02-06T11:51:25+00:00 https://glenmarkpharma.com/other_announcements/change-in-senior-management-august-2023/ 2026-02-06T11:53:33+00:00 https://glenmarkpharma.com/other_announcements/regulation-30-lodr-change-in-directorate/ 2026-02-06T11:56:59+00:00 https://glenmarkpharma.com/other_announcements/result-of-postal-ballot-by-remote-e-voting-scrutinizers-report-4/ 2026-02-06T12:01:49+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-saxagliptin-tablets-2-5-mg-and-5-mg/ 2026-02-06T12:03:55+00:00 https://glenmarkpharma.com/other_announcements/regulation-30-lodr-updates-on-acquisition/ 2026-02-06T12:15:21+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-for-transfer-of-equity-shares-to-iepf-authority/ 2026-02-06T12:18:23+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-regulation-47-of-sebi-listing-obligations-and-disclosure-requirements-regulations-2015/ 2026-02-06T12:21:52+00:00 https://glenmarkpharma.com/other_announcements/notice-of-postal-ballot-disclosure-under-regulation-30-of-the-sebi-lodr-regulations-2015-3/ 2026-02-06T12:34:32+00:00 https://glenmarkpharma.com/other_announcements/update-on-the-companys-monroe-north-carolina-usa-facility/ 2026-02-06T12:40:06+00:00 https://glenmarkpharma.com/other_announcements/exchange-notification-glenmark-becomes-a-part-of-the-science-based-targets-initiative-sets-ghg-emissions-targets-for-fy-2035/ 2026-02-06T12:45:04+00:00 https://glenmarkpharma.com/other_announcements/incorporation-of-a-wholly-owned-subsidiary-company/ 2026-02-07T08:46:56+00:00 https://glenmarkpharma.com/other_announcements/result-of-postal-ballot-by-remote-e-voting-scrutinizers-report-5/ 2026-02-07T09:42:46+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-calcipotriene-and-betamethasone-dipropionate-foam-0-0050-064/ 2026-02-07T09:46:13+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-prochlorperazine-maleate-tablets-usp-5-mg-and-10-mgagm-date-intimation-copy/ 2026-02-07T09:49:39+00:00 https://glenmarkpharma.com/other_announcements/glenmark-receives-acceptance-from-u-s-fda-on-its-ind-application-for-grc-54276-to-proceed-with-a-phase-1-2-first-in-human-clinical-study-of-the-molecule-for-the-treatment-of-patients-with-advanced-s/ 2026-02-07T09:53:16+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-postal-ballot-notice-4/ 2026-02-07T09:56:56+00:00 https://glenmarkpharma.com/other_announcements/notice-of-postal-ballot-disclosure-under-regulation-30-of-the-sebi-lodr-regulations-2015-4/ 2026-02-07T10:00:20+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-anda-approval-for-clindamycin-hydrochloride-capsules-usp-75-mg-150-mg-and-300-mg/ 2026-02-07T10:04:08+00:00 https://glenmarkpharma.com/other_announcements/glenmark-and-cediprof-announce-exclusive-distribution-agreement-in-the-united-states-for-u-s-fda-approved-dextroamphetamine-saccharate-amphetamine-aspartate-dextroamphetamine-sulfate-and-amphetamin/ 2026-02-07T10:07:26+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-receives-2nd-anda-tentative-approval-for-saxagliptin-tablets-2-5-mg-and-5-mg/ 2026-02-07T10:09:45+00:00 https://glenmarkpharma.com/other_announcements/glenmark-launches-akynzeo-i-v-in-india-first-fixed-i-v-antiemetic-combination-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting/ 2026-02-07T10:17:45+00:00 https://glenmarkpharma.com/other_announcements/heart-failure-treatment-becomes-more-affordable-with-glenmark-launching-the-sacubitril-valsartan-tablets-in-india/ 2026-02-07T10:22:35+00:00 https://glenmarkpharma.com/other_announcements/glenmark-pharmaceuticals-launches-bumetanide-injection-usp-1-mg-4-ml-0-25-mg-ml-single-dose-vials-and-2-5-mg-10-ml-0-25-mg-ml-multi-dose-vials/ 2026-02-07T10:28:57+00:00 https://glenmarkpharma.com/other_announcements/credit-ratings-rating-rationale-issued-by-india-ratings-and-research-3/ 2026-02-09T10:07:21+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-interim-dividend/ 2026-02-09T10:49:14+00:00 https://glenmarkpharma.com/other_announcements/newspaper-advertisement-special-window-uploaded-on-bse-and-nse/ 2026-02-18T12:21:24+00:00 https://glenmarkpharma.com/other_announcements/general-updates-esg-rating/ 2026-02-20T18:41:45+00:00 https://glenmarkpharma.com/other_announcements/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-requirements-regulations-2015-regulatory-action-inspection/ 2026-04-01T18:43:10+00:00